Skip to content

Effects of two types of anesthesia maintenance on body immunity and malignant behaviours of patients after cancer surgery

Effects of two types of anesthesia maintenance on body immunity and malignant behaviours of patients after cancer surgery: a prospective, randomized, controlled pilot study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16008128
Enrollment
Unknown
Registered
2016-03-22
Start date
2016-03-22
Completion date
Unknown
Last updated
2017-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant solid tumors

Interventions

Sevoflurane groupin in each tumor type:Sevoflurane for inhalation
Propofol groupin in each tumor type:Propofol for injection

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 90 years, no gender and race limit; 2. Patient that is scheduled for elective radical surgery in general anesthesia. Radical surgery means that the aim of the surgery is to cure; 3. Primary malignant tumor (including breast cancer, non-small cell lung cancer, gastric adenocarcinoma, pancreatic carcinoma, prostate cancer, clear cell renal cell carcinoma, colorectal adenocarcinoma, serous ovarian carcinoma and cervical cancer), about 60 patients will be enrolled from each tumor type; 4. Agree to participate, and give signed written informed consent.

Exclusion criteria

Exclusion criteria: 1. Refuse to join; 2. The surgery that is going to be made is an acute surgical procedure or palliative surgery; 3. Critical illness (preoperative American Society of Anesthesiologists physical status classification = IV), severe renal dysfunction (undergoing dialysis before surgery), or severe hepatic dysfunction (Child-Pugh class C); 4. Other reasons that are considered unsuitable for participation by the responsible surgeons or investigators (reasons must be recorded in the case report form).

Design outcomes

Primary

MeasureTime frame
The expression of hypoxia-induced molecules;

Secondary

MeasureTime frame
The number of tumor-infiltrating lymphocytes;Early postoperative immune function;

Countries

China

Contacts

Public ContactWang Dong-xin

Peking University First Hospital

wangdongxin@hotmail.com+86 13910731903

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026